Compared to controls, the BC-treated group exhibited reduced weight loss, improved histological outcomes, and lower expression levels of key inflammatory mediators such as TLR4, IL-1β, IL-8, and IL-10, while TNF-α levels remained unchanged. The gene discussed is TLR4; the disease is breast cancer.